Ankush Paladhi

About

Ankush Paladhi is an Indian immunologist specializing in Cancer Immunology and translational immunological research. He earned his PhD in Cancer Immunology from The University of Burdwan under the supervision of Dr. Sumit Kumar Hira. He subsequently pursued two years of postdoctoral research as an IPDF in Prof. Anirban Banerjee’s laboratory at IIT Bombay, followed by six months as a Research Scientist in Dr. Rupesh K. Srivastava’s laboratory at AIIMS, New Delhi. He is currently an ANRF-NPDF in Prof. Dipankar Nandi’s laboratory at the Indian Institute of Science (IISc), Bangalore. His scholarly contributions also include serving as a peer reviewer for leading international journals, including Frontiers in Immunology, Frontiers in Oncology, PLOS ONE, Scientific Reports, BMC Cancer, Medical Oncology, and International Immunopharmacology.

Employment

• Indian Institute of Science Bangalore ANRF-NPDF (National Postdoctoral Fellow)
  2026 - Present
• All India Institute of Medical Sciences Research Scientist
  2026 - 2026
• Indian Institute of Technology Bombay Institutional Postdoctoral Fellow (IPDF)
  2023 - 2025
• University of Oklahoma Health Sciences Center Postdoctoral Fellow
  2023 - 2023

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (18)

• Gut-Associated Metabolites (GAMs) revitalize dysfunctional CD8⁺ T lymphocytes in Osteosarcoma
  2026 DOI: 10.64898/2026.07.30.741694
  +Save
• TLR7-Induced Mitochondrial Reactive Oxygen Species Production in Monocyte-derived Dendritic Cells Drives IL-12–Dependent NK Cell Activation and Enhances Antitumor Immunity
  The Journal of Immunology 2024 DOI: 10.4049/jimmunol.2400340
  +Save
• Estimates of differential toxin expression governing heterogeneous intracellular lifespans of Streptococcus pneumoniae
  Journal of Cell Science 2024 DOI: 10.1242/jcs.260891
  +Save
• Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma
  International Immunopharmacology 2023 DOI: 10.1016/j.intimp.2022.109521
  +Save
• Bioactive ZnO‐assisted 1393 glass scaffold promotes osteogenic differentiation: Some studies
  Journal of Biomedical Materials Research Part B: Applied Biomaterials 2022 DOI: 10.1002/jbm.b.35214
  +Save
• γc cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1
  Cytotherapy 2022 DOI: 10.1016/j.jcyt.2022.07.012
  +Save
• Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity
  Frontiers in Immunology 2022 DOI: 10.3389/fimmu.2022.988071
  +Save
• PGC1 alpha coactivates ERG fusion to drive antioxidant target genes under metabolic stress
  Communications Biology 2022 DOI: 10.1038/s42003-022-03385-x
  +Save
• Nanoscale Diamond-Based Formulation as an Immunomodulator and Potential Therapeutic for Lymphoma
  Frontiers in Pharmacology 2022 DOI: 10.3389/fphar.2022.852065
  +Save
• Targeting PD-1 in CD8+ T Cells with a Biomimetic Bilirubin-5-fluoro-2-deoxyuridine–Bovine Serum Albumin Nanoconstruct for Effective Chemotherapy against Experimental Lymphoma
  Molecular Pharmaceutics 2021 DOI: 10.1021/acs.molpharmaceut.1c00050
  +Save